News & Updates

Patients with early-stage nonsmall cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) have similar overall survival (OS) regardless of nodal staging, reports a study. In addition, use of SBRT has shown a steady increase over the study period.

Infection with COVID-19 may increase the risk of pulmonary fibrosis, and patients with a severe disease are at greater risk of developing this complication, suggests a recent study.

Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.

Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.

In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).

Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options. 

Depression levels among adults appear to be positively associated with respiratory symptoms, asthma, and chronic obstructive pulmonary disease (COPD), according to a study.